CN117769414A - 用于治疗代谢疾病的乳酰氨基酸 - Google Patents

用于治疗代谢疾病的乳酰氨基酸 Download PDF

Info

Publication number
CN117769414A
CN117769414A CN202280034413.4A CN202280034413A CN117769414A CN 117769414 A CN117769414 A CN 117769414A CN 202280034413 A CN202280034413 A CN 202280034413A CN 117769414 A CN117769414 A CN 117769414A
Authority
CN
China
Prior art keywords
lac
phe
lactoyl
subject
exercise
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034413.4A
Other languages
English (en)
Chinese (zh)
Inventor
乔纳森·隆
维罗妮卡·李
史蒂文·巴尼克
徐勇
何洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Leland Stanford Junior University
Original Assignee
Baylor College of Medicine
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Leland Stanford Junior University filed Critical Baylor College of Medicine
Publication of CN117769414A publication Critical patent/CN117769414A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280034413.4A 2021-05-04 2022-05-02 用于治疗代谢疾病的乳酰氨基酸 Pending CN117769414A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183868P 2021-05-04 2021-05-04
US63/183,868 2021-05-04
PCT/US2022/027261 WO2022235557A1 (en) 2021-05-04 2022-05-02 Lactoyl amino acids for the treatment of metabolic disease

Publications (1)

Publication Number Publication Date
CN117769414A true CN117769414A (zh) 2024-03-26

Family

ID=83932803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280034413.4A Pending CN117769414A (zh) 2021-05-04 2022-05-02 用于治疗代谢疾病的乳酰氨基酸

Country Status (7)

Country Link
US (1) US20240189266A1 (https=)
EP (1) EP4313297A4 (https=)
JP (1) JP2024516969A (https=)
KR (1) KR20240006050A (https=)
CN (1) CN117769414A (https=)
AU (1) AU2022271191A1 (https=)
WO (1) WO2022235557A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119350175A (zh) * 2024-10-15 2025-01-24 广东药科大学 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240122888A1 (en) * 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of phenylalanine and lactate
CN116035217B (zh) * 2022-12-23 2023-08-04 暨南大学 一种具有减肥减脂作用的组合物与应用
WO2024192165A1 (en) * 2023-03-14 2024-09-19 The Board Of Trustees Of The Leland Stanford Junior University N-beta-hydroxybutyryl-amino acids and related compositions and methods
WO2025072489A2 (en) * 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2025184353A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating metabolic disorders
CN118795011B (zh) * 2024-06-28 2025-01-21 合肥工业大学 一种用于细胞代谢产物n-l-乳酰-l-苯丙氨酸的快速检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159146A (zh) * 1995-07-26 1997-09-10 弗门尼舍有限公司 风味产品及其制备方法
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
WO2012054528A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119350175A (zh) * 2024-10-15 2025-01-24 广东药科大学 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途
CN119350175B (zh) * 2024-10-15 2026-03-17 广东药科大学 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途

Also Published As

Publication number Publication date
WO2022235557A1 (en) 2022-11-10
US20240189266A1 (en) 2024-06-13
EP4313297A4 (en) 2024-09-18
EP4313297A1 (en) 2024-02-07
JP2024516969A (ja) 2024-04-18
KR20240006050A (ko) 2024-01-12
AU2022271191A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN117769414A (zh) 用于治疗代谢疾病的乳酰氨基酸
Yuan et al. Exercise‐induced α‐ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1‐dependent adrenal activation
Zhang et al. Intestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis
M’Kadmi et al. N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor
Perez-Baos et al. Mediators and patterns of muscle loss in chronic systemic inflammation
Turroni et al. Microbiota–host transgenomic metabolism, bioactive molecules from the inside: Miniperspective
Tiwari et al. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders
Binder et al. Leucine supplementation protects from insulin resistance by regulating adiposity levels
Pozzo-Miller et al. Rett syndrome: reaching for clinical trials
Wang et al. Metabolic rescue of α-synuclein-induced neurodegeneration through propionate supplementation and intestine-neuron signaling in C. elegans
Fan et al. Evodiamine inhibits zymosan-induced inflammation in vitro and in vivo: inactivation of NF-κB by inhibiting IκBα phosphorylation
Huang et al. M2 macrophages secrete glutamate-containing extracellular vesicles to alleviate osteoporosis by reshaping osteoclast precursor fate
Lee et al. PGC-1α functions as a co-suppressor of XBP1s to regulate glucose metabolism
Mao et al. Ferroptosis: a potential bridge linking gut microbiota and chronic kidney disease
Zheng et al. Carbon monoxide-releasing molecules reverse leptin resistance induced by endoplasmic reticulum stress
Ma et al. HDAC5-mTORC1 interaction in differential regulation of ghrelin and nucleobindin 2 (NUCB2)/nesfatin-1
Li et al. Novel pentapeptide derived from chicken by-product ameliorates DSS-induced colitis by enhancing intestinal barrier function via AhR-induced Src inactivation
Jang et al. Free essential amino acid feeding improves endurance during resistance training via DRP1‐dependent mitochondrial remodelling
Park et al. HMBA ameliorates obesity by MYH9‐and ACTG1‐dependent regulation of hypothalamic neuropeptides
Lin et al. Homocysitaconate controls inflammation through reshaping methionine metabolism and N-homocysteinylation
Li et al. Kynurenic Acid, a Small Foodborne Molecule with the Potential to Affect Human Health
Africano et al. Identification of a histone deacetylase inhibitor as a therapeutic candidate for congenital central hypoventilation syndrome
Ding et al. Nuciferine activates intestinal TAS2R46 to attenuate metabolic disorders and hyperlipidemia via hepatic VLDL regulation
La Spina et al. Multiple mechanisms converging on transcription factor EB activation by the natural phenol pterostilbene
Qi et al. How to explain exercise-induced phenotype from molecular data: rethink and reconstruction based on AMPK and mTOR signaling

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination